Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Summary

  • A total of 24% of participants in the DRIVE-SHIFT trial,[Johnson 2019] which evaluated a switch to doravirine/lamivudine/tenofovir DF in virologically suppressed patients on stable ART for ≥ 6 months with no previous virologic failure or resistance to doravirine if they were on NNRTI-based regimens before the switch
  • Among those who entered the study on regimens including an NNRTI, 94.3% vs 96.4%, respectively, reached the primary endpoint. Participants who had a history of NNRTI mutations—K103N, Y181C, or G190A—also had good results, with 90.9% of those who switched to doravirine/lamivudine/tenofovir DF and 100% who maintained their baseline regimen had HIV-1 RNA < 50 copies/mL at Week 48. No resistance to doravirine developed in either treatment group

Action required